Erica Richards
Researcher at the National Institute of Mental Health (NIMH)
Data updated
Papers
Trials
Research Footprint
Erica Richards appears in 6 tracked papers (2014–2017), most studied alongside Ketamine, across Depressive Disorders, Bipolar Disorder and Suicidality.
Most-cited paper: Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety (283 citations).
Frequent co-authors: Carlos Zarate, Mark John Niciu and David Luckenbaugh.
Background & Research
Erica M. Richards appears as an author on multiple NIMH ketamine/depression papers from the NIH Intramural Research Program. PubMed lists her affiliation with the National Institute of Mental Health in Bethesda, Maryland, and one paper gives her NIH email address, indicating she was a research scientist or clinician-scientist at NIMH. Her publications include work on ketamine’s antidepressant and anti-suicidal effects, as well as a review of NMDA receptor antagonists in depression.
Key Impact
Clinical research contributor to early ketamine studies in depression, including anxious bipolar depression and suicidal ideation.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Erica Richards is associated with.
National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →National Institutes of Health (NIH)
U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.
View stakeholder →